Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexeo Therapeutics, Inc. - Common Stock
(NQ:
LXEO
)
6.470
+0.270 (+4.35%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
170,471
Open
6.230
Bid (Size)
6.200 (1)
Ask (Size)
6.600 (53)
Prev. Close
6.200
Today's Range
6.200 - 6.720
52wk Range
5.770 - 22.33
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 13, 2024
Via
Benzinga
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
August 12, 2024
LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-56.37%
-56.37%
1 Month
-33.91%
-33.91%
3 Month
-46.31%
-46.31%
6 Month
-58.15%
-58.15%
1 Year
-42.74%
-42.74%
More News
Read More
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
July 15, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 15, 2024
Via
Benzinga
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
July 15, 2024
Via
Benzinga
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
July 15, 2024
Via
Investor's Business Daily
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
July 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
May 07, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
April 22, 2024
Via
Benzinga
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
April 22, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
April 16, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
March 13, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
March 12, 2024
Via
Benzinga
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
March 11, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
March 11, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
March 06, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
February 05, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 18, 2024
Via
Benzinga
Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
January 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
LEXEO Therapeutics
Via
GlobeNewswire
Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday
December 26, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
December 18, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
December 11, 2023
Via
InvestorPlace
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
December 11, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
